Schizophrenia and Addiction

Chapter
First Online:

Abstract

Substance use disorders are highly prevalent among people with schizophrenia. Dually diagnosed patients present with unfavorable course and poor long-term outcomes. Integrated, motivation-based treatment for both disorders in the same setting is considered the treatment of choice for this challenging population. Treatment programs include state-of-the-art pharmacotherapy and psychosocial interventions such as motivational interviewing, psychoeducation, and cognitive–behavioral approaches.

Keywords

Atypical Antipsychotic Motivational Interview Extrapyramidal Side Effect Epidemiological Catchment Area Secondary Development 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. Bechdolf A, Pohlmann B, Güttgemanns J et al (2012) State-dependent motivational interviewing for people with schizophrenia and substance use: results of a randomised controlled trial. Nervenarzt 83:888–896PubMedCrossRefGoogle Scholar
  2. Bennett ME, Bellack AS, Gearon JS (2001) Treating substance abuse in schizophrenia. An initial report. J Subst Abuse Treat 20:163–175PubMedCrossRefGoogle Scholar
  3. Blanchard JJ, Brown SA, Horan WP, Sherwood AR (2000) Substance use disorders in schizophrenia: review, integration, and a proposed model. Clin Psychol Rev 20:207–234PubMedCrossRefGoogle Scholar
  4. Borgwardt SJ, Riecher-Rossler A, Dazzan P (2007) Regional gray matter volume abnormalities in the at risk mental state. Biol Psychiatry 61:1148–1156PubMedCrossRefGoogle Scholar
  5. Cassidy CM, Schmitz N, Malla A (2008) Validation of the alcohol use disorders identification test and the drug abuse screening test in first episode psychosis. Can J Psychiatry 53:26–33PubMedGoogle Scholar
  6. Chambers RA, Krystal JH, Self DW (2001) A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol Psychiatry 50:71–83PubMedCentralPubMedCrossRefGoogle Scholar
  7. Cleary M, Hunt GE, Matheson SL, Siegfried N, Walter G (2010) Psychosocial interventions for people with both severe mental illness and substance misuse. The Cochrane Collaboration. Editorial Group: Cochrane Schizophrenia Group. WileyGoogle Scholar
  8. D’Amelio R, Behrendt BWT (2007) Psychoedukation Schizophrenie und Sucht. Manual zur Leitung von Patienten-und Angehörigengruppen. Elsevier/Urban and Fischer, MunichGoogle Scholar
  9. De Witte NA, Crunelle CL, Sabbe B, Moggi F, Dom G (2013) Treatment for outpatients with comorbid schizophrenia and substance use disorders: a review. Eur Addict Res 20:105–114PubMedCrossRefGoogle Scholar
  10. Drake RE, Mueser KT (2000) Psychosocial approaches to dual diagnosis. Schizophr Bull 26:105–118PubMedCrossRefGoogle Scholar
  11. Drake RE, Mueser KT, Brunette MF, McHugo GJ (2004) A review of treatments for people with severe mental illnesses and co-occurring substance use disorders. Psychiatr Rehabil J 27:360–374PubMedCrossRefGoogle Scholar
  12. Drake RE, O’Neal EL, Wallach MA (2008) A systematic review of psychosocial research on psychosocial interventions for people with co-occurring severe mental and substance use disorders. J Subst Abuse Treat 34:123–138PubMedCrossRefGoogle Scholar
  13. Duke PJ, Pantelis C, McPhillips MA, Barnes TRE (2001) Comorbid non-alcohol substance misuse among people with schizophrenia. Br J Psychiatry 179:509–513PubMedCrossRefGoogle Scholar
  14. Gouzoulis-Mayfrank E (2007) Komorbidität Psychose und Sucht—Grundlagen und Praxis—Mit Manualen für die Psychoedukation und Verhaltenstherapie, 2nd edn. Steinkopff, DarmstadtGoogle Scholar
  15. Green AI, Noordsy DL, Brunette MF, O’Keefe C (2008) Substance abuse and schizophrenia: pharmacotherapeutic intervention. J Subst Abuse Treat 34:61–71PubMedCentralPubMedCrossRefGoogle Scholar
  16. Lazary J (2012) Psychopharmacological boundaries of schizophrenia with comorbid cannabis use disorder: a critical review. Curr Pharm Des 18:4890–4896PubMedCrossRefGoogle Scholar
  17. Lowe AL, Abou-Saleh MT (2004) The British experience of dual diagnosis in the national health service. Acta Neuropsychiatrica 16:41–46CrossRefGoogle Scholar
  18. Moggi F, Brodbeck J, Költzsch K, Hirsbrunner H-P, Bachmann KM (2002) One-year follow-up of dual diagnosis patients attending a 4-month integrated inpatient treatment. Eur Addict Res 8:30–37PubMedCrossRefGoogle Scholar
  19. Moore TH, Zammit S, Lingford-Hughes A et al (2007) Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 370:319–328PubMedCrossRefGoogle Scholar
  20. Morrens M, Dewilde B, Sabbe B, Dom G, De Cuyper R, Moggi F (2011) Treatment Outcomes of an Integrated Residential Programme for patients with schizophrenia and substance use disorder. Eur Addict Res 17:154–163PubMedCrossRefGoogle Scholar
  21. Mueser KT, Fox L (2002) A family intervention program for dual disorders. Community Ment Health J 38:253–270PubMedCrossRefGoogle Scholar
  22. Mueser KT, Drake RE, Wallach MA (1998) Dual diagnosis: a review of etiological theories. Addict Behav 23:717–734PubMedCrossRefGoogle Scholar
  23. Mueser KT, Yarnold PR, Rosenberg SD, Swett C Jr, Miles KM, Hill D (2000) Substance use disorder in hospitalized severely mentally ill psychiatric patients: prevalence, correlates, and subgroups. Schizophr Bull 26:179–192PubMedCrossRefGoogle Scholar
  24. Petrakis IL, Poling J, Levinson C, Nich C, Carroll K, Rounsaville B (2005) Naltrexone and disulfiram in patients with alcohol dependence and comorbid psychiatric disorders. Biol Psychiatry 57:1128–1137PubMedCrossRefGoogle Scholar
  25. Ralevski E, O’Brien E, Jane S, Dean E, Dwan R, Petrakis I (2011) Effects of acamprosate in a treatment study of patients with schizophrenia spectrum disorders and comorbid alcohol dependence. J Nerv Mental Dis 199:499–505CrossRefGoogle Scholar
  26. Regier DA, Farmer ME, Rae DS et al (1990) Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 264:2511–2518PubMedCrossRefGoogle Scholar
  27. Rubio G, Martínez I, Ponce G, Jiménez-Arriero MA, López-Muñoz F, Alamo C (2006) Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. Can J Psychiatry 51:531–539PubMedGoogle Scholar
  28. Schnell T, Koethe D, Krasnianski A, Gairing S, Schnell K, Daumann J, Gouzoulis-Mayfrank E (2014) Ziprasidone versus clozapine in the treatment of dually diagnosed (DD) patients with schizophrenia and cannabis use disorders: a randomized study. Am J Addict 23:308–312PubMedCrossRefGoogle Scholar
  29. Sinha R, Garcia M, Paliwal P, Kreek MJ, Rounsaville BJ (2006) Stress-induced cocaine craving and hypothalamic-pituitary-adrenal responses are predictive of cocaine relapse outcome. Arch Gen Psychiatry 63:324–331PubMedCrossRefGoogle Scholar
  30. Volkow ND, Wang GJ, Fowler JS, Tomasi D, Telang F (2011) Addiction: beyond dopamine reward circuitry. Proc Natl Acad Sci U S A 108:15037–15042PubMedCentralPubMedCrossRefGoogle Scholar
  31. Walter M, Denier N, Vogel M, Lang UE (2012) Effects of psychoactive substances in schizophrenia. Curr Top Med Chem 12:2426–2433PubMedCrossRefGoogle Scholar
  32. Walter M, Gerber H, Kuhl HC et al (2013) Acute effects of intravenous diacetylmorphine on the hypothalamic-pituitary-adrenal axis response. J Clin Psychopharmacol 33:193–198PubMedCrossRefGoogle Scholar
  33. Wright IC, Rabe-Hesketh S, Woodruff PW, David AS, Murray RM, Bullmore ET (2000) Meta-analysis of regional brain volumes in schizophrenia. Am J Psychiatry 157:16–25PubMedGoogle Scholar
  34. Ziedonis DM, D’Avanzo K (1998) Schizophrenia and substance abuse. In: Kranzler HR, Rounsaville BJ (eds) Dual diagnosis and treatment. Marcel Dekker, New York, pp 427–465Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Department of Psychiatry and Psychotherapy IILVR Clinics CologneCologneGermany
  2. 2.Department of Psychiatry and PsychotherapyUniversity Hospital of CologneCologneGermany
  3. 3.Department of PsychiatryUniversity of BaselBaselSwitzerland

Personalised recommendations